Jul 27, 2025, 16:56

Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

Supports studies to develop, test, and refine strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, spread, and de-implementation of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies across clinical, public health, and community settings .

Eligibility Criteria:

U.S. and foreign organizations, including higher-education institutions; nonprofits (501(c)(3) and others); for-profit entities (small businesses and others); local, state, tribal, and federal government agencies; and community- and faith-based organizations .
Applicant institutions must complete SAM (or NCAGE), obtain a UEI, register in eRA Commons (PD/PI & SO accounts), and Grants.gov before submission.
PD/PI must hold an eRA Commons account; institutional Signing Officials require a separate account.
Applications may optionally propose an NIH-defined clinical trial, but clinical trials are not required.

Funding Details:

Budgets are unlimited but must reflect actual project needs; project period up to 5 years.
Number of awards depends on NIH appropriations and meritorious applications.
Funds may cover personnel, intervention and implementation strategy development, data collection and analysis, contextual assessment, economic evaluations, stakeholder engagement, and dissemination activities .

Deadline:

All applications are due by 5:00 PM local time on one of the following dates:

February 5, 2025
June 5, 2025
October 5, 2025
February 5, 2026
June 5, 2026
October 5, 2026
February 5, 2027
June 5, 2027
October 5, 2027

(Expiration: January 8, 2028)

Where to Go for Further Information:

Funding Opportunity Number: PAR-25-144 (search via NIH ASSIST, Grants.gov Workspace, or institutional S2S).
For Grants.gov technical assistance: [email protected]

Community Engagement de-implementation Dissemination evidence-based interventions Health Disparities Implementation Science NIH PAR-25-144 policy implementation R01 scale-up sustainability

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth